The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project

oleh: Monica Bellei, Francine M. Foss, Andrei R. Shustov, Steven M. Horwitz, Luigi Marcheselli, Won Seog Kim, Maria E. Cabrera, Ivan Dlouhy, Arnon Nagler, Ranjana H. Advani, Emanuela A. Pesce, Young-Hyeh Ko, Virginia Martinez, Silvia Montoto, Carlos Chiattone, Alison Moskowitz, Michele Spina, Irene Biasoli, Martina Manni, Massimo Federico

Format: Article
Diterbitkan: Ferrata Storti Foundation 2018-07-01

Deskripsi

This analysis explored factors influencing survival of patients with primary refractory and relapsed peripheral T-cell lymphomas enrolled in the prospective International T-cell Project. We analyzed data from 1020 patients with newly diagnosed disease, enrolled between September 2006 and December 2015. Out of 937 patients who received first-line treatment, 436 (47%) were identified as refractory and 197 (21%) as relapsed. Median time from the end of treatment to relapse was 8 months (range 2-73). Overall, 75 patients (8%) were consolidated with bone marrow transplantation, including 12 refractory and 22 relapsed patients. After a median follow up of 38 months (range 1-96 months) from documentation of refractory/relapsed disease, 440 patients had died. The median overall survival (OS) was 5.8 months; 3-year overall survival rates were 21% and 28% for refractory and relapsed patients, respectively (P